U.S. markets open in 3 hours 35 minutes
  • S&P Futures

    4,577.00
    +5.75 (+0.13%)
     
  • Dow Futures

    35,274.00
    +15.00 (+0.04%)
     
  • Nasdaq Futures

    15,240.00
    +34.00 (+0.22%)
     
  • Russell 2000 Futures

    2,096.00
    +3.90 (+0.19%)
     
  • Crude Oil

    86.75
    +1.32 (+1.55%)
     
  • Gold

    1,819.00
    +6.60 (+0.36%)
     
  • Silver

    23.82
    +0.33 (+1.40%)
     
  • EUR/USD

    1.1351
    +0.0021 (+0.18%)
     
  • 10-Yr Bond

    1.8650
    0.0000 (0.00%)
     
  • Vix

    22.43
    +3.24 (+16.88%)
     
  • GBP/USD

    1.3626
    +0.0028 (+0.21%)
     
  • USD/JPY

    114.4820
    -0.1030 (-0.09%)
     
  • BTC-USD

    41,464.91
    -536.96 (-1.28%)
     
  • CMC Crypto 200

    985.11
    -24.28 (-2.41%)
     
  • FTSE 100

    7,574.56
    +11.01 (+0.15%)
     
  • Nikkei 225

    27,467.23
    -790.02 (-2.80%)
     

Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., November 11, 2021--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 15 at 3:20pm ET.

A live webcast of the fireside chat can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005295/en/

Contacts

Investor Contact
Helen Rubinstein
315-382-3979
Helen.Rubinstein@sagerx.com

Media Contact
Maureen L. Suda
617-949-4289
Maureen.Suda@sagerx.com